{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:21:12Z","timestamp":1791778872804,"version":"4.3.4"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T00:00:00Z","timestamp":1179705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Splenectomy has traditionally been considered as a standard first line treatment for splenic marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy. However it carries significant complications, especially in elderly patients. The purpose of this retrospective study was to report our experience on the efficacy of Rituximab as first line treatment in 16 consecutive SMZL patients, diagnosed in our department. The diagnosis was established using standard criteria. Patients' median age was 57 years (range, 48\u201378). Prior to treatment initiation all patients had splenomegaly, nine had anemia, five lymphocytosis, five neutropenia and six thrombocytopenia. Rituximab was administered at a dose of 375 mg\/m<jats:sup>2<\/jats:sup>\/week for 6 consecutive weeks. The overall response rate was 100%. After treatment, all patients had a complete resolution of splenomegaly along with restoration of their blood counts. Eleven patients (69%) achieved a CR, three (19%) unconfirmed CR and two (12%) a PR. Among the complete responders seven patients had also a molecular remission. The median time to clinical response was 3 weeks (range, 2\u20136). Rituximab maintenance was given to 12 patients. Eleven of them had no evidence of disease progression after a median follow\u2010up time of 28.5 months (range, 14\u201336), while two out of four patients who did not receive maintenance, relapsed 7 and 24 months after the completion of induction treatment. Median follow\u2010up time for the entire series was 29.5 months (range, 15\u201381). No deaths were recorded during the follow\u2010up period. Therapy was well tolerated. The present study demonstrates that rituximab is an effective treatment for SMZL and could be considered as a substitute or alternative to splenectomy. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.820","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T11:48:05Z","timestamp":1179748085000},"page":"127-131","source":"Crossref","is-referenced-by-count":83,"title":["Rituximab monotherapy is highly effective in splenic marginal zone lymphoma"],"prefix":"10.1002","volume":"25","author":[{"given":"C","family":"Kalpadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GA","family":"Pangalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MN","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TP","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2010C","family":"Kyrtsonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Korkolopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FN","family":"Kontopidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MP","family":"Siakantaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EM","family":"Dimitriadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SI","family":"Kokoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tsaftaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MK","family":"Angelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5,21]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2010  American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris NL","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostics factors in a series of 60 patients","volume":"100","author":"Chacon JI","year":"2002","journal-title":"Blood"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.010"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W"},{"key":"e_1_2_1_8_2","first-page":"307","article-title":"Clinical presentation and management of marginal zone lymphomas","author":"Thieblemont C","year":"2005","journal-title":"ASH Educ Book"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_1_10_2","first-page":"1578","article-title":"Rituximab in patients with mucosa\u2010associated lymphoid tissue\u2010type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri AJ","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_1_11_2","first-page":"794","article-title":"Comparison of different polymerase chain reaction\u2010based approaches for clonality assessment of immunoglobulin heavy\u2010chain gene rearrangements in B\u2010cell neoplasia","volume":"12","author":"Derksen PWB","year":"1999","journal-title":"Mod Pathol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x"},{"key":"e_1_2_1_13_2","first-page":"148","article-title":"Splenic lymphoma with circulating villous lymphocytes\/ splenic marginal\u2010zone lymphoma","volume":"36","author":"Catovsky D","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401710"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245330512331389755"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.717"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009054887"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3523168.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074641"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.2174\/156802606778194235"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.128"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_1_24_2","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett M","year":"2005","journal-title":"Haematol\/Haematol J"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21931"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.820","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:11:35Z","timestamp":1700035895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,21]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/hon.820"],"URL":"https:\/\/doi.org\/10.1002\/hon.820","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,21]]}}}